Drugs / HER2 BATs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03661424 | Feb 2019 → Dec 2021 | female breast carcinoma, malignant leptomeningeal tumor | University of Virginia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03272334 | Dec 2017 → Nov 2024 overdue | breast cancer | University of Virginia | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Her2 BATs | “8 weekly infusions of Her2 BATs delivered into the ventricle of the brain.” NCT03661424 ↗ |
| Known as | HER2 Bi-armed activated T-cells (BATs) | “Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)” NCT03661424 ↗ |
| Modality | Cell therapy | “HER2Bi armed activated T-cells (HER2 BATs)” NCT03272334 ↗ |
| Route | Other | “Infusions are given intraventricularly.” NCT03661424 ↗ |